Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 105 peer-reviewed journal articles Updated
Gynecologic Oncology

Cervical Cancer: A Patient Guide

At a Glance

Treatment for cervical cancer depends on its stage, cell type, overall health, and personal goals. Early cancer may be treated with surgery; locally advanced disease often needs chemoradiation and brachytherapy, while recurrent or metastatic cancer may need drug treatment and long-term follow-up.

Cervical cancer is a condition that primarily develops in the cells lining the cervix, the lower part of the uterus that connects to the vagina. For the vast majority of people, the primary cause of this cancer is a persistent infection with high-risk strains of HPV (Human Papillomavirus) [1]. While most HPV infections clear on their own, when high-risk strains remain active in the cervical tissue for years, they can disrupt the cells’ natural growth controls, leading to precancer and eventually invasive cancer [2][3]. Although the precancerous phase takes years to develop, once an invasive cancer is diagnosed, timely staging and a prompt treatment plan are necessary.

Because every cancer is different, treatment decisions must be individualized. They depend heavily on the stage of the disease, the specific cell type (histology), your overall health, and your personal goals. Your care should be guided by a multidisciplinary team, including a gynecologic oncologist, radiation oncologist, and medical oncologist.

For early-stage disease, where the tumor is small and confined to the cervix, surgery is often the primary approach [4]. Depending on specific tumor characteristics, some patients may be candidates for fertility-preserving surgeries, while others may require a hysterectomy or the removal of lymph nodes [5]. Modern research helps surgeons tailor these operations, allowing selected patients with low-risk tumors to undergo less extensive procedures [6].

When the cancer has grown deeper into the surrounding pelvic tissues—a stage known as “locally advanced”—the standard of care usually involves a combination of chemoradiation and brachytherapy [7]. This approach uses weekly chemotherapy alongside daily external-beam radiation, followed by or integrated with internal radiation (brachytherapy). Brachytherapy is an essential, curative component of this plan [8]. For specific high-risk patients, newer treatments like the immunotherapy drug pembrolizumab may be added to this regimen [9][10].

If the cancer is metastatic (has spread to distant organs) or has recurred, the focus moves toward systemic therapies or individualized surgical/radiation plans. Systemic options include chemotherapy, immunotherapy (like pembrolizumab, depending on specific tumor markers like PD-L1), and targeted therapies [11]. Drugs like bevacizumab can improve outcomes but carry specific risks, such as bleeding or bowel/bladder complications, particularly in patients who have had prior pelvic radiation [12][13]. For subsequent lines of treatment, targeted drugs like tisotumab vedotin provide options but require strict safety protocols, such as a rigorous eye-care plan to prevent ocular toxicity [14][15].

Survivorship is a long-term commitment. Because treatments can affect pelvic health, bone density, and organ function, survivors transition into a phase of holistic care [16][17]. This includes regular clinical exams and a focus on managing “late effects” that may emerge months or years later, such as changes in sexual health, premature menopause, or lymphedema [18][19]. The goal of this phase is not just to monitor for recurrence, but to support your physical, emotional, and practical needs for a full life after treatment [20].

In this guide

6 chapters

01

Understanding Your Cervical Cancer Diagnosis & Biology

Learn how HPV, tumor histology, and rare cervical cancer subtypes shape diagnosis, treatment planning, and emotional support after a cervical cancer diagnosis.

02

Staging, Imaging, and Pathology Reports

Learn how cervical cancer staging, MRI and PET/CT findings, and pathology reports show tumor size, lymph node spread, LVSI, margins, and treatment plans.

03

Treatment for Early-Stage Cervical Cancer

Learn how early-stage cervical cancer treatment uses conization, hysterectomy, lymph node checks, fertility-preserving options, and postoperative therapy.

04

Treatment for Locally Advanced & Metastatic Cervical Cancer

Learn how locally advanced and metastatic cervical cancer are treated with chemoradiation, immunotherapy, brachytherapy, and targeted drugs, including key risks.

05

Managing Side Effects and Survivorship Quality of Life

Learn how to manage cervical cancer late effects, including vaginal, bladder, bowel, bone, menopause, lymphedema, sexual, and emotional health after treatment.

06

Monitoring, Follow-up, and Warning Signs

Learn how cervical cancer follow-up works after treatment, including visit schedules, scans, warning signs, survivorship care, and when to seek urgent help.

Common questions in this guide

What is the usual treatment for early-stage cervical cancer?
When cervical cancer is small and confined to the cervix, surgery is often the main treatment. Selected patients may be eligible for fertility-preserving surgery, while others may need a hysterectomy and removal of lymph nodes. The choice depends on tumor features and personal goals.
How is locally advanced cervical cancer treated?
When cervical cancer has grown into surrounding pelvic tissues, treatment usually combines weekly chemotherapy with daily external-beam radiation. Brachytherapy, which delivers radiation from inside the body, is then included or integrated and is an important part of the curative plan.
Can cervical cancer treatment include immunotherapy?
Yes. Pembrolizumab may be added for some high-risk locally advanced cases, and immunotherapy may also be used for recurrent or metastatic disease when tumor features such as PD-L1 support it. Your oncology team will determine whether it fits your cancer.
What treatments are available if cervical cancer returns or spreads?
Recurrent or metastatic cervical cancer may be treated with chemotherapy, immunotherapy, or targeted drugs, and some people may need an individualized surgery or radiation plan. Bevacizumab can improve outcomes but may increase bleeding or bowel and bladder complications, especially after pelvic radiation. Tisotumab vedotin is another option after earlier treatments, but it requires a strict eye-care plan.
What causes most cervical cancers?
Most cervical cancers are linked to a persistent infection with a high-risk type of human papillomavirus, or HPV. Most HPV infections clear on their own, but infections that remain active for years can cause precancerous changes and eventually invasive cancer.
What does survivorship care involve after cervical cancer treatment?
Survivorship care includes regular clinical exams and attention to late effects that can affect pelvic health, bone density, sexual health, premature menopause, or urinary and bowel function. It may also address lymphedema and emotional or practical needs, while helping determine when imaging is appropriate.

Get notified when new evidence is published on cervical cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (20)
  1. 1

    Molecular, immunological and oncogenic mechanisms of cervical cancer mediated by HPV/HIV co-infection, clinical implication and management.

    Terkimbi SD, Paul-Chima UO, Mujinya R, et al.

    Infectious agents and cancer 2025; (21(1)):12 doi:10.1186/s13027-025-00729-0.

    PMID: 41469918
  2. 2

    Therapeutic targeting of the HPV E7 oncoprotein: Current advances and emerging strategies.

    Gholami S, Aghbash PS, Ravanlo ZZ, et al.

    International immunopharmacology 2026; (172()):116193 doi:10.1016/j.intimp.2026.116193.

    PMID: 41570748
  3. 3

    The Natural History of Cervical Cancer and the Case for MicroRNAs: Is Human Papillomavirus Infection the Whole Story?

    Palomino-Vizcaino G, Bañuelos-Villegas EG, Alvarez-Salas LM

    International journal of molecular sciences 2024; (25(23)) doi:10.3390/ijms252312991.

    PMID: 39684702
  4. 4

    ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer.

    Schmeler KM, Pareja R, Lopez Blanco A, et al.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2021; (31(10)):1317-1325 doi:10.1136/ijgc-2021-002921.

    PMID: 34493587
  5. 5

    Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer.

    Plante M, Kwon JS, Ferguson S, et al.

    The New England journal of medicine 2024; (390(9)):819-829 doi:10.1056/NEJMoa2308900.

    PMID: 38416430
  6. 6

    Statement of the Uterus Commission of the Gynecological Oncology Working Group (AGO) on Surgical Therapy for Patients with Stage IA2-IIB1 Cervical Cancer.

    Fehm T, Beckmann MW, Mahner S, et al.

    Geburtshilfe und Frauenheilkunde 2023; (83(10)):1199-1204 doi:10.1055/a-2160-3279.

    PMID: 37808259
  7. 7

    Radiation therapy for cervical cancer in Uganda: a practice guideline.

    Kibudde S, Kavuma A, Abal B, et al.

    Ecancermedicalscience 2025; (19()):1999 doi:10.3332/ecancer.2025.1999.

    PMID: 41561518
  8. 8

    CT versus MRI for Image-Guided Brachytherapy in Locally Advanced Cervical Cancer: A Propensity Score-Matched Analysis.

    Nagar A, Samanta A, Chopra S, et al.

    International journal of radiation oncology, biology, physics 2026; (125(4)):1111-1120 doi:10.1016/j.ijrobp.2026.01.041.

    PMID: 41692354
  9. 9

    Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

    Lorusso D, Xiang Y, Hasegawa K, et al.

    Lancet (London, England) 2024; (404(10460)):1321-1332 doi:10.1016/S0140-6736(24)01808-7.

    PMID: 39288779
  10. 10

    Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.

    Lorusso D, Xiang Y, Hasegawa K, et al.

    Lancet (London, England) 2024; (403(10434)):1341-1350 doi:10.1016/S0140-6736(24)00317-9.

    PMID: 38521086
  11. 11

    Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNOTE-826 Randomized Clinical Trial.

    Hasegawa K, Colombo N, Tewari KS, et al.

    JAMA oncology 2026; doi:10.1001/jamaoncol.2026.3547.

    PMID: 42720936
  12. 12

    Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

    Tewari KS, Sill MW, Penson RT, et al.

    Lancet (London, England) 2017; (390(10103)):1654-1663 doi:10.1016/S0140-6736(17)31607-0.

    PMID: 28756902
  13. 13

    Gastrointestinal/genitourinary perforation and fistula formation with or without bevacizumab in patients with previously irradiated recurrent cervical cancer: a Korean multicenter retrospective study of the Gynecologic Oncology Research Investigators Collaboration (GORILLA) group (GORILLA-1001).

    Hwang WY, Chang SJ, Kim HS, et al.

    BMC cancer 2022; (22(1)):603 doi:10.1186/s12885-022-09695-x.

    PMID: 35655188
  14. 14

    Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.

    Vergote I, González-Martín A, Fujiwara K, et al.

    The New England journal of medicine 2024; (391(1)):44-55 doi:10.1056/NEJMoa2313811.

    PMID: 38959480
  15. 15

    Mitigation and management strategies for ocular events associated with tisotumab vedotin.

    Kim SK, Ursell P, Coleman RL, et al.

    Gynecologic oncology 2022; (165(2)):385-392 doi:10.1016/j.ygyno.2022.02.010.

    PMID: 35277279
  16. 16

    American Brachytherapy Society Working Group Report on cancer surveillance, sexual health, and pelvic toxicity management in gynecologic malignancies.

    Quick A, Garda A, Rivera A, et al.

    Brachytherapy 2026; (25(4)):559-568 doi:10.1016/j.brachy.2026.03.010.

    PMID: 41982027
  17. 17

    Surveillance and Care of the Gynecologic Cancer Survivor.

    Faubion SS, MacLaughlin KL, Long ME, et al.

    Journal of women's health (2002) 2015; (24(11)):899-906 doi:10.1089/jwh.2014.5127.

    PMID: 26208166
  18. 18

    Follow-up for cervical cancer: a Program in Evidence-Based Care systematic review and clinical practice guideline update.

    Elit L, Kennedy EB, Fyles A, Metser U

    Current oncology (Toronto, Ont.) 2016; (23(2)):109-18 doi:10.3747/co.23.2742.

    PMID: 27122975
  19. 19

    A systematic review of the impact of contemporary treatment modalities for cervical cancer on women's self-reported health-related quality of life.

    Wiltink LM, King M, Müller F, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2020; (28(10)):4627-4644 doi:10.1007/s00520-020-05554-2.

    PMID: 32556622
  20. 20

    [Follow-up after radiation therapy for cervical cancer].

    Cao KI, Mazeron R, Barillot I

    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 2015; (19(6-7)):590-6.

    PMID: 26282216

This page is for informational purposes only and does not constitute medical advice about cervical cancer treatment or survivorship. Your gynecologic, radiation, and medical oncology team can interpret your results and recommend care for your situation.